QQ客服 官方微博 反馈留言

	Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B
	Chen, Liang; Janssen, Harry L. A.; Hansen, Bettina E.; Tabak, Fehmi; Liem, Kin Seng; van Campenhout, Margo J. H.; Xie, Qing; Brouwer, Willem Pieter; Chi, Heng; Qi, Xun
刊名	ALIMENTARY PHARMACOLOGY & THERAPEUTICS
	2019
卷号	49期号:4
ISSN号	0269-2813
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594749
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Chen, Liang,Janssen, Harry L. A.,Hansen, Bettina E.,et al. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS,2019,49(4).
APA	Chen, Liang.,Janssen, Harry L. A..,Hansen, Bettina E..,Tabak, Fehmi.,Liem, Kin Seng.,...&Qi, Xun.(2019).Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B.ALIMENTARY PHARMACOLOGY & THERAPEUTICS,49(4).
MLA	Chen, Liang,et al."Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B".ALIMENTARY PHARMACOLOGY & THERAPEUTICS 49.4(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。